Introduction To develop an effective and targeted therapeutic approach for solid tumors, including cervical cancer, with improved survival rates compared to standard treatments. Overcoming barriers to immunotherapies in solid tumors, such as limited therapy half-life, tumor penetrance, and precise targeting, is crucial. We aim to explore a durable and controllable local delivery method for therapeutic proteins, which can enhance antitumor efficacy while minimizing non-tumor tissue toxicities.

Methods The Anti-Tissue factor x CD3 TCE is composed of two Tissue factor binding Fabs, which allow for preferential recognition of Tissue factor-high-expressing cancer cells, and one CD3 binding domain that facilitates Tissue factor-mediated CD3 crosslinking and subsequent T cell activation. Flow cytometry was used to study activation and degranulation assays. The immunomodulatory function of this sentence was able to confirm in vitro cell killing analysis through luciferase reporter cell analysis.

Results Our study demonstrated that the functional tissue factor-targeted BiTE protein induced T cell activation, degranulation, and antigen-specific killing of cervical cancer cells. Importantly, this response was specific to tissue factor expression and was not observed in the absence of tissue factor expression.

Conclusion/Implications The findings support the potential of the BiTE protein as a targeted therapeutic approach for cervical cancer, offering a promising strategy to address the challenges associated with solid tumors and improve treatment outcomes.